SCHEMBL4907060

SCHEMBL4907060

N#Cc1c(SCC(N)=O)nc(NC2CC2)nc1-c1ccccc1OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.43
▸ TSHR P16473 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ HPGD P15428 5/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ ADORA2B P29275 2/20 0.40
▸ HTR1B P28222 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ ADORA1 P30542 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ MAPT P10636 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4900982 0.83 ALDH1A1 (0.48) ALDH1A1TSHRSMN1; SMN2HPGDKDM4E
SCHEMBL4905880 0.82 MAPK8 (0.40) ALDH1A1MEN1KMT2AMAPK8MAPK9
SCHEMBL4904086 0.80 ACHE (0.43) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL4907483 0.77 ALDH1A1 (0.46) ALDH1A1TSHRSMN1; SMN2HPGDKDM4E
SCHEMBL4908412 0.73 ALDH1A1 (0.50) ALDH1A1TSHRSMN1; SMN2HPGDKDM4E
SCHEMBL4909704 0.72 ADORA2B (0.44) ALDH1A1TSHRSMN1; SMN2HPGDKDM4E
SCHEMBL4897863 0.72 BACE1 (0.47) ALDH1A1TSHRSMN1; SMN2HPGDKDM4E
SCHEMBL4909720 0.71 MAPT (0.51) ALDH1A1TSHRSMN1; SMN2HPGDKDM4E
SCHEMBL4906551 0.71 BRAF (0.63) —
SCHEMBL4908408 0.70 ALDH1A1 (0.42) ALDH1A1TSHRSMN1; SMN2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 — — EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 — — US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ALDH1A1 1662/4885TSHR 1074/4885SMN1; SMN2 3598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback